Virax Biolabs Group Limited - T-Cell Immune Response Diagnostics Innovator

Company Overview (Updated April 2026)

Virax Biolabs Group Limited is a biotechnology company headquartered in Lanarkshire, United Kingdom. Founded in 2013, the company is focused on the detection of immune responses and diagnosis of viral diseases through innovative T-cell-based in vitro diagnostics (IVD). The company completed its initial public offering in July 2022 on the Nasdaq Capital Market under the ticker symbol VRAX at an offering price of $5.00 per share.

Mission: To develop and commercialize innovative diagnostic solutions that detect immune responses to viral diseases, enabling earlier diagnosis and improved management of conditions such as Long COVID and other post-viral syndromes.

Corporate History and Development (2013-2026)

Founding and Early Operations (2013-2021)

- 2013: Company founded; originally incorporated as Virax Biolabs (Cayman) Limited before changing name to Virax Biolabs Group Limited in September 2021

- Operations: Established operating subsidiaries in Singapore, China, Hong Kong, and the British Virgin Islands, with executive offices in London

IPO and Public Market Entry (2022)

- July 2022: Completed IPO on Nasdaq Capital Market, offering 1,350,000 ordinary shares at $5.00 per share, raising approximately $6.75 million gross proceeds

- Underwriter: Boustead Securities, LLC

- Co-founders: James Foster (CEO, beneficially owned 28.7% pre-IPO) and Cameron Shaw (COO, beneficially owned 20.8% pre-IPO)

Strategic Partnerships and Research (2024-2025)

- August 2025: Entered distribution agreement with Europa Biosite to commercialize ImmuneSelect Research Use portfolio in the UK and Ireland through Cambridge BioScience

- August 2025: Partnered with Emory University for Long COVID diagnostic research, positioning technology as a potential solution for millions of patients lacking effective diagnostic options

- 2025: Expanded distribution of RT PCR Mpox virus detection kits in Europe and GCC region; kits feature 96.7% sensitivity and 93.72% specificity with results in under 70 minutes

Core Product Portfolio

ViraxClear™ Diagnostic Test Kits

A comprehensive range of in-vitro diagnostics test kits including:

- Respiratory Disease Tests: Detection kits for respiratory viral infections

- Infectious Disease Tests: Broad portfolio for viral and bacterial pathogen detection

- STI Tests: Sexually transmitted infection diagnostics

- Cardiac Markers: Cardiovascular diagnostic tests

- Women's Health Tests: Specialized diagnostics for women's health conditions

- Oncology Tests: Cancer marker detection kits

- Pregnancy and Fertility Tests: Reproductive health diagnostics

ViraxVet™ Veterinary Diagnostics

- Rapid and molecular tests for small animal veterinary diagnostics

- Expanding portfolio for veterinary infectious disease detection

ViraxImmune™ T-Cell IVD Platform

- Technology: T-cell in vitro diagnostic device paired with a wellness mobile application

- Focus: Immune status profiling and adaptive immunity assessment

- Target Conditions: Post-viral syndromes including Long COVID, and other chronic conditions associated with immune dysregulation

ImmuneSelect™ Research Portfolio

- Purpose: Research products dedicated to investigating adaptive immunity

- Peptide Pools: Covering epitopes from pathogens including SARS-CoV-2, Lyme Disease, CMV, RSV, and EBV

- Recombinant Antibodies: Targeting cytokines and biomarkers for Flow Cytometry, ELISA, and ELISpot/Fluorospot applications

- Status: For research and investigational use only (RUO)

RT PCR Mpox Virus Detection Kit

- Sensitivity: 96.7%

- Specificity: 93.72%

- Turnaround Time: Results in under 70 minutes

- Regulatory Status: CE marked and UK MHRA authorized

Research and Development

- Long COVID Research: Collaboration with Emory University to develop diagnostics for Long COVID and other post-viral conditions

- T-Cell Technology: Developing immunology profiling platform considered particularly effective for diagnosing post-viral syndromes

- AI Integration: Exploring machine learning applications for immune response data analysis

Global Presence

- Headquarters: Lanarkshire, United Kingdom

- Executive Office: 30 Broadwick Street, London, W1F 8LX, United Kingdom

- Operating Subsidiaries: Singapore, china (Shanghai), Hong Kong, British Virgin Islands

- Markets: United Kingdom, United States, China, and Europe (via distribution partners)

Financial Performance (2025)

Key Financial Metrics (TTM as of September 2025)

- Revenue (TTM): Approximately $6,331

- Cost of Revenue (TTM): $59,398

- Gross Profit (TTM): -$53,067

- Net Income (TTM): -$6.06 million

- Diluted EPS (TTM): -$1.62

- Total Cash: $4.32 million

- Total Debt/Equity: 13.08%

- Levered Free Cash Flow: -$3.25 million

- Return on Equity: -114.47%

- Return on Assets: -64.68%

Stock Performance (2026)

- Current Price: ~$0.39 (as of late 2025/early 2026)

- Market Cap: ~$1.70 million (December 2025)

- 52-Week Range: $0.35 - $3.20

- YTD Return (2026): 56.68% (as of April 17, 2026)

- Price/Book Ratio: 0.30

- Price/Sales Ratio: 231.27

Analyst Coverage (2026)

- Consensus Rating: Buy (HC Wainwright & Co.)

- Price Target: $3.00 (implying +663.55% upside potential from current levels)

Regulatory and Compliance Matters (2025)

- Nasdaq Compliance: Received notice of non-compliance regarding minimum bid price requirement ($1.00) on July 14, 2025; granted 180-calendar-day compliance period through January 12, 2026

- CE Marking: Mpox detection kits carry CE mark for European distribution

- MHRA Authorization: Mpox kits authorized by UK Medicines and Healthcare products Regulatory Agency

Leadership Team

Executive Leadership

Chief Executive Officer, Chairman & Principal Accounting Officer: James Foster

- Co-founder; born 1985

- Beneficially owned approximately 28.7% of ordinary shares pre-IPO

- Total compensation: $457,440 (2024 fiscal year)

Chief Operating Officer & Director: Cameron Shaw

- Co-founder

- Beneficially owned approximately 20.8% of ordinary shares pre-IPO

Chief Scientific Officer & Co-founder: Tomasz George

Chief Operating Officer (Operations): Dr. Nigel McCracken, M.Sc., Ph.D.

- Total compensation: $448,040 (2024 fiscal year)

Vice President of Investor Relations: Richard Pallin

Head of Scientific Research & Development: Clement Monteil

Head of Supply Chain: Lily Fu

Independent Director (appointed 2025): Dr. Iain Miller

- Over 30 years of experience in diagnostics and medical technology sectors

- Replaced Yair Erez

Company Information

Corporate Details

Legal Name: Virax Biolabs Group Limited

Former Name: Virax Biolabs (Cayman) Limited

Founded: 2013

Headquarters: Lanarkshire, United Kingdom

Executive Office: 30 Broadwick Street, London, W1F 8LX, United Kingdom

Registered Office (Cayman Islands): Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009

Stock Exchange: Nasdaq Capital Market

Ticker Symbol: VRAX

Status: Public company (foreign private issuer, Cayman Islands-incorporated)

Industry: Biotechnology / In Vitro Diagnostics / T-Cell Diagnostics / Immune Response Detection

Employees: Small team (exact number not publicly disclosed)

Contact Information

Phone: +44 020 7788 7414

Website: www.viraxbiolabs.com

Investor Relations: investors.viraxbiolabs.com

Keywords: Virax Biolabs, VRAX, T-cell diagnostics, immune response, Long COVID, viral diseases, in vitro diagnostics, James Foster, Cameron Shaw, Lanarkshire, London, Nasdaq, ImmuneSelect, ViraxClear, ViraxVet, ViraxImmune, Europa Biosite, Emory University, Mpox, CE mark, MHRA, 2013 founded, Cayman Islands